32
Treatment
4.2.9. Weight Management
COR LOE
Recommendations
1 C-EO 1. In patients with CCD, assessment of BMI with or without
waist circumference is recommended during routine clinical
follow-up.
1 B-NR 2. Patients with CCD and overweight or obesity should receive
counseling on diet, lifestyle, and goals for weight loss.
2a B-R 3. For patients with CCD and overweight or obesity in whom
pharmacologic therapy is warranted for further weight
reduction, a GLP-1 receptor agonist can be beneficial in
addition to counseling for diet and physical activity, and it is
reasonable to choose semaglutide over liraglutide.
2a B-NR 4. In patients with CCD and severe obesity who have not
met weight loss goals with lifestyle and pharmacologic
intervention, and who have acceptable surgical risk, referral
for consideration of a bariatric procedure is reasonable for
weight loss and cardiovascular risk factor reduction.
3: Harm B-R 5. In patients with CCD, use of sympathomimetic weight loss
drugs is potentially harmful.
4.2.10. Cardiac Rehabilitation
COR LOE
Recommendations
1 A*
1. All patients with CCD and appropriate indications*
†‡
should
be referred to a cardiac rehabilitation program to improve
outcomes.
B-R
†
C-LD
‡
* Aer recent MI, PCI, or CABG.
†
With stable angina or aer heart transplant.
‡
Aer recent spontaneous coronary artery dissection event.
